Drugs / CLBS16
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04614467 | Oct 2020 → Sep 2022 | coronary microvascular disorder | Lisata Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03508609 | Apr 2018 → Dec 2019 | coronary microvascular disorder | Lisata Therapeutics, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-05-14 | Lisata Therapeutics, Inc. | Results Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions lisata.com ↗
today presented full data results from the ESCaPE-CMD trial of Caladrius’s autologous CD34+ cell therapy, CLBS16, at the Society for Cardiovascular Angiography and Interventions (“SCAI”) 2020 Scientific Sessions Virtual Conference. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-01-19 | Lisata Therapeutics, Inc. | Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction lisata.com ↗ |
| 2020-05-14 | Lisata Therapeutics, Inc. | Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions lisata.com ↗ |
| 2020-05-06 | Lisata Therapeutics, Inc. | Caladrius Biosciences Announces Presentation of Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions lisata.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLBS16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03508609 ↗ |
| Known as | Autologous CD34+ cells | “Autologous CD34+ cells (CLBS16) were mobilized by administration of granulocyte-colony stimulating factor 5µg/kg/day for 5 days and collected by leukapheresis.” PMID 35067072 ↗ Jan 2022 |
| Action | Restore | “The resulting restoration of the microcirculation improves myocardial tissue perfusion, resulting in the recovery of coronary microvascular function” PMID 34066713 ↗ May 2021 |
| Modality | Cell therapy | “Autologous CD34+ stem cell therapy increases coronary flow reserve and reduces angina in patients with coronary microvascular dysfunction.” PMID 35067072 ↗ Jan 2022 |
| Route | Other | “Participants received a single intracoronary left anterior descending infusion of isolated CD34+ cells in medium that enhances cell function.” PMID 35067072 ↗ Jan 2022 |